HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Sutro Biopharma (NASDAQ:STRO) and maintained a price target of $12, indicating confidence in the company's future performance.
September 16, 2024 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Sutro Biopharma and maintained a $12 price target, suggesting positive expectations for the company's stock performance.
The reiteration of a Buy rating and maintenance of a $12 price target by HC Wainwright & Co. indicates a positive outlook for Sutro Biopharma. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100